XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Stockholders’ Deficit - USD ($)
$ in Thousands
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2023   4,015,002      
Balance, beginning of period at Dec. 31, 2023 $ (27,065) $ 0 $ 2 $ 222,437 $ (249,504)
Balances, beginning of period (in shares) at Dec. 31, 2023     26,413,213    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (13,206)       (13,206)
Exercise of options (in shares) [1]     (4,941)    
Exercise of options and vesting of restricted stock units (in shares)     2,906    
Exercise of options and vesting of restricted stock units [1] 7     7  
Issuance of common stock through employee stock purchase plan (in shares) [2]     55,670    
Issuance of common stock through employee stock purchase plan [2] 37     37  
Stock-based compensation 1,086     1,086  
Proceeds from sale of common stock (in shares)     350,000    
Proceeds from sale of common stock 3,141     3,141  
Ending balance (in shares) at Mar. 31, 2024   4,015,002      
Balance, end of period at Mar. 31, 2024 (36,037) $ 0 $ 2 226,671 (262,710)
Balances, end of period (in shares) at Mar. 31, 2024     26,758,272    
Beginning balance (in shares) at Dec. 31, 2023   4,015,002      
Balance, beginning of period at Dec. 31, 2023 (27,065) $ 0 $ 2 222,437 (249,504)
Balances, beginning of period (in shares) at Dec. 31, 2023     26,413,213    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (19,937)        
Ending balance (in shares) at Sep. 30, 2024   3,985,002      
Balance, end of period at Sep. 30, 2024 (20,434) $ 0 $ 3 249,004 (269,441)
Balances, end of period (in shares) at Sep. 30, 2024     30,469,664    
Beginning balance (in shares) at Mar. 31, 2024   4,015,002      
Balance, beginning of period at Mar. 31, 2024 (36,037) $ 0 $ 2 226,671 (262,710)
Balances, beginning of period (in shares) at Mar. 31, 2024     26,758,272    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (4,332)       (4,332)
Exercise of options and vesting of restricted stock units (in shares)     1,191    
Exercise of options and vesting of restricted stock units 5     5  
Stock-based compensation 1,275     1,275  
Proceeds from sale of common stock (in shares)     400,000    
Proceeds from sale of common stock 3,602     3,602  
Record exchange warrants 11,923     11,923  
Record issuance costs (1,699)     (1,699)  
Ending balance (in shares) at Jun. 30, 2024   4,015,002      
Balance, end of period at Jun. 30, 2024 (25,263) $ 0 $ 2 241,777 (267,042)
Balances, end of period (in shares) at Jun. 30, 2024     27,159,463    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (2,399)       (2,399)
Exercise of options and vesting of restricted stock units (in shares)     660    
Exercise of options and vesting of restricted stock units 2     2  
Issuance of common stock through employee stock purchase plan (in shares) [2]     49,939    
Issuance of common stock through employee stock purchase plan [2] 278     278  
Stock-based compensation 1,300     1,300  
Preferred stock conversion (in shares)   (30,000) 32,645    
Proceeds from sale of common stock (in shares)     1,116,591    
Proceeds from sale of common stock 5,648   $ 1 5,647  
Record exchange warrants (in shares)     2,110,366    
Ending balance (in shares) at Sep. 30, 2024   3,985,002      
Balance, end of period at Sep. 30, 2024 $ (20,434) $ 0 $ 3 249,004 (269,441)
Balances, end of period (in shares) at Sep. 30, 2024     30,469,664    
Beginning balance (in shares) at Dec. 31, 2024 3,985,002 3,985,002      
Balance, beginning of period at Dec. 31, 2024 $ (25,894) $ 0 $ 3 253,652 (279,549)
Balances, beginning of period (in shares) at Dec. 31, 2024 31,279,264   31,279,264    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ (10,375)       (10,375)
Exercise of options and vesting of restricted stock units (in shares)     159,699    
Exercise of options and vesting of restricted stock units 279     279  
Stock-based compensation 1,583     1,583  
Preferred stock conversion (in shares)   (365,000) 777,829    
Ending balance (in shares) at Mar. 31, 2025   3,620,002      
Balance, end of period at Mar. 31, 2025 $ (34,370) $ 0 $ 3 255,551 (289,924)
Balances, end of period (in shares) at Mar. 31, 2025     32,272,462    
Beginning balance (in shares) at Dec. 31, 2024 3,985,002 3,985,002      
Balance, beginning of period at Dec. 31, 2024 $ (25,894) $ 0 $ 3 253,652 (279,549)
Balances, beginning of period (in shares) at Dec. 31, 2024 31,279,264   31,279,264    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ (29,474)        
Ending balance (in shares) at Sep. 30, 2025 0 0      
Balance, end of period at Sep. 30, 2025 $ (26,725) $ 0 $ 4 294,241 (320,970)
Balances, end of period (in shares) at Sep. 30, 2025 49,891,299   49,891,299    
Beginning balance (in shares) at Mar. 31, 2025   3,620,002      
Balance, beginning of period at Mar. 31, 2025 $ (34,370) $ 0 $ 3 255,551 (289,924)
Balances, beginning of period (in shares) at Mar. 31, 2025     32,272,462    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (8,288)       (8,288)
Exercise of options and vesting of restricted stock units (in shares)     155,051    
Exercise of options and vesting of restricted stock units 56     56  
Stock-based compensation [3] 2,517     2,517  
Preferred stock conversion (in shares)   (26,000) 55,746    
Proceeds from sale of common stock (in shares)     5,500,000    
Proceeds from sale of common stock 20,662     20,662  
Ending balance (in shares) at Jun. 30, 2025   3,594,002      
Balance, end of period at Jun. 30, 2025 (19,423) $ 0 $ 3 278,786 (298,212)
Balances, end of period (in shares) at Jun. 30, 2025     37,983,259    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (10,811)       (10,811)
Exercise of options and vesting of restricted stock units (in shares)     45,042    
Exercise of options and vesting of restricted stock units 88     88  
Issuance of common stock through employee stock purchase plan (in shares) [2]     49,939    
Issuance of common stock through employee stock purchase plan [2] 50     50  
Stock-based compensation 3,371     3,371  
Preferred stock conversion (in shares)   (3,594,002) 11,813,059    
Preferred stock conversion $ 0   $ 1 11,946 (11,947)
Ending balance (in shares) at Sep. 30, 2025 0 0      
Balance, end of period at Sep. 30, 2025 $ (26,725) $ 0 $ 4 $ 294,241 $ (320,970)
Balances, end of period (in shares) at Sep. 30, 2025 49,891,299   49,891,299    
[1]
(3) Amount reflects 2,906 shares issued for option exercises and 7,847 shares returned from options exercised in 2023 to correct clerical error.
[2]
(2) The Company records the issuance of the shares when they are recorded by the transfer agent and as such, there could be timing differences between when the expense is recorded and shares are transferred.
[3]
(1) Amount reflects $0.6 million related to 2024 bonus paid in 2025 in the form of stock-based compensation.